Revenue numbersFirst I apologize for not reading my posts before posting. I made a lot of mistakes in spelling, grammer and probably syntax.
Q4 2021 numbers guesses anyone? More than than Q4 2020 $25M and inline with Q3 2021 $31M to $32M or slightly higher at $35M
Next treo coming to Canada possibly in June.
Treosulfan: On February 2, 2021, the Company entered into an exclusive license to commercialize treosulfan in the United States. The Prescription Drug User Fee Act date is scheduled for August 2021 with potential to commercialize shortly thereafter. In accordance with the Orphan Drug Act, seven years of exclusivity for this indication is expected upon FDA approval. The current market leading alkylating agent for Allo-HSCT reached peak sales of US$126M in the U.S. As announced by the Company on September 10, 2020, Health Canada granted priority review for treosulfan, which could be approved as early as June 2021. Medexus is currently negotiating the licence in anticipation of a full commercial launch following Health Canada approval.
We should see revenues from Gleolan as well
Gleolan®: On February 25, 2021, Medexus initiated commercial launch of Gleolan® in Canada, replacing use under the Health Canada Special Access Program.
Not sure what is happening with Triamcinolone Hexacetonide (TH) They were supposed to get, if I read it correctly, import ok in US from FDA before being able to sell (market) the drug which is in short supply.